We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+3.47%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$147M
AUM Growth
+$1.82M
Cap. Flow
+$9.13M
Cap. Flow %
6.21%
Top 10 Hldgs %
77.72%
Holding
45
New
3
Increased
5
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$5.45M
2
GTLB icon
GitLab
GTLB
+$1.32M
3
MELI icon
Mercado Libre
MELI
+$1.03M
4
MRUS
Merus
MRUS
+$997K
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$172K

Top Sells

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$63K
2
SYBX
Synlogic
SYBX
+$52.2K
3
EAR
Eargo, Inc. Common Stock
EAR
+$8

Sector Composition

Rank Sector Weight
1 Healthcare 98.32%
2 Technology 0.86%
3 Consumer Discretionary 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$41M 27.89%
225,688
– –
ILMN icon
2
Illumina
ILMN
$31B
$27.7M 18.86%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$12M 8.19%
368,665
– –
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$9.54M 6.49%
47,096
– –
OCS icon
5
Oculis Holding
OCS
$683M
$4.84M 3.29%
+651,100
New +$5.45M
EXAI
6
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.56M 3.1%
859,892
+6,842
+0.8% +$46.4K
SLGC
7
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.33M 2.94%
1,696,558
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.06B
$4.09M 2.79%
114,380
– –
REPL icon
9
Replimune Group
REPL
$941M
$3.34M 2.28%
189,339
– –
MRUS
10
DELISTED
Merus
MRUS
$2.78M 1.89%
151,000
+57,250
+61% +$997K
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.72M 1.85%
111,984
– –
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.64M 1.8%
113,950
– –
ONC
13
BeOne Medicines Ltd
ONC
$32.8B
$2.59M 1.76%
12,022
– –
RANI icon
14
Rani Therapeutics
RANI
$87M
$2.55M 1.73%
493,584
– –
INCY icon
15
Incyte
INCY
$24.2B
$2.49M 1.69%
34,391
– –
BMEA icon
16
Biomea Fusion
BMEA
$84.6M
$1.86M 1.27%
60,000
– –
BOLT icon
17
Bolt Biotherapeutics
BOLT
$7.67M
$1.62M 1.1%
58,348
– –
PACB icon
18
Pacific Biosciences
PACB
$435M
$1.58M 1.08%
136,655
– –
GRTX
19
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.57M 1.07%
613,223
– –
GTLB icon
20
GitLab
GTLB
$5.83B
$1.27M 0.86%
36,952
+30,042
+435% +$1.32M
EXEL icon
21
Exelixis
EXEL
$13.3B
$1.25M 0.85%
64,200
– –
MELI icon
22
Mercado Libre
MELI
$95.2B
$1.19M 0.81%
+904
New +$1.03M
TRDA icon
23
Entrada Therapeutics
TRDA
$264M
$1.07M 0.73%
73,582
– –
JBIO
24
Jade Biosciences
JBIO
$1.2B
$967K 0.66%
1,370
-76
-5% -$63K
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.6B
$702K 0.48%
7,215
+1,100
+18% +$114K
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q1 2023 Portfolio in Review

As of Q1 2023, Nan Fung Group Holdings held 45 positions worth $147M, up 1.3% from $145M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Nan Fung Group Holdings deployed $9.13M of net new capital in Q1 2023, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Oculis Holding: 651,100 shares worth $4.84M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Jade Biosciences, an estimated $63K trimmed.

  • Nan Fung Group Holdings's largest Q1 2023 buy was Oculis Holding: 651,100 shares worth $4.84M.
  • Nan Fung Group Holdings added most to GitLab in Q1 2023, an estimated $1.32M increase.
  • Nan Fung Group Holdings's biggest Q1 2023 reduction was Jade Biosciences, cutting an estimated $63K.
  • Nan Fung Group Holdings fully exited Synlogic in Q1 2023, selling an estimated $52.2K.
  • Nan Fung Group Holdings's ten largest holdings make up 78% of its $147M portfolio in Q1 2023.
  • Nan Fung Group Holdings opened 3 new positions and closed 1 in Q1 2023.
  • Nan Fung Group Holdings's portfolio value rose 1.3% quarter-over-quarter to $147M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2023, filed 12 May 2023.